Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Cordis

This article was originally published in The Gray Sheet

Executive Summary

Cordis: Firm's three-dimensional electrophysiology mapping technology, acquired through an August licensing agreement with Biosense ("The Gray Sheet" Aug. 7, In Brief), "has been successfully tested in initial human clinical cases" in Israel, Cordis says. "A three-dimensional reconstruction" of the right atrium's electrical activity with 35 data points were successfully produced in two patients, the firm says. The maps were produced within five minutes, the company states, noting that "with conventional electrophysiology, such a mapping procedure could take as much as two hours to perform." Additional trials slated for the next several weeks will "involve mapping of atrial fibrillation and ventricular tachycardias," Cordis says...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT004974

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel